DUSP9 and metabolic dysfunction-associated steatotic liver disease: In recent studies, DUSP9 has been revealed to participate in inflammatory responses in the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) via p38 and JNK signaling pathways [25].